Millennium Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Millennium Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-95,000	Closed	-$1.91M	–	6623
2023 Q3	$1.91M	Buy	95,000 +45,700	+93%	+$1.16M	﹤0.01%	3593
2023 Q2	$1.39M	Buy	+49,300	New	+$1.18M	﹤0.01%	3774
2022 Q1	–	Sell	-15,000	Closed	-$1.26M	–	7583
2021 Q4	$1.26M	Buy	+15,000	New	+$1.16M	﹤0.01%	4190

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Millennium Management's ZNTL Position: Q1 2026 in Review

Millennium Management increased its Zentalis Pharmaceuticals (ZNTL) stake by 92% in Q1 2026, buying an estimated $1.59M and bringing the position to 1,289,822 shares worth $3.02M. The position accounts for ﹤0.01% of the portfolio, ranked #3455.

Millennium Management first reported a position in ZNTL in Q1 2021 and has held it in 18 quarters since. The position peaked at $8.97M in Q3 2023. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

Millennium Management held 1,289,822 shares of Zentalis Pharmaceuticals worth $3.02M as of Q1 2026.
Millennium Management bought 616,693 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $1.59M.
Zentalis Pharmaceuticals made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3455 holding.
Millennium Management first reported a position in Zentalis Pharmaceuticals in Q1 2021 and has held it in 18 quarters since.
Millennium Management's Zentalis Pharmaceuticals position peaked at $8.97M in Q3 2023.
102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.